Friedreich’s Ataxia

Omaveloxolone is currently the only approved treatment for Friedreich's ataxia, so other options are needed. Sulforaphane, a compound found in broccoli and other cruciferous vegetables, had previously been shown to raise frataxin levels in sensory nerve cells grown from a patient's stem cells. This study extends that work with further preclinical testing in the same kind of patient derived neurons. These are laboratory results, not a trial in people, and the compound has not been shown to help patients.

Friedreich's ataxia and Huntington's disease are both caused by stretches of repeated DNA that grow too long, but the damage differs. In Friedreich's ataxia the expanded GAA repeat sits in an intron of the FXN gene and silences it, leaving too little frataxin. This review examines how CRISPR gene editing might tackle that, including cutting the expanded repeat out and reversing the chemical silencing to reawaken the gene, and is candid about the delivery and safety hurdles that remain.

A 10 year old girl was diagnosed with acute myeloid leukaemia and Friedreich's ataxia at the same time and received a stem cell transplant for the leukaemia. The transplant cured the cancer without major complications, and afterwards her blood frataxin levels returned to normal and her heart muscle thickening decreased. Her neurological symptoms, however, progressed as they would have otherwise. The case suggests a transplant can correct blood and heart features but does not reach the nervous system.

Friedreich's ataxia affects many body systems and needs a team of different specialists. This systematic review searched three medical databases for studies published between 2010 and 2025 on both drug and non drug treatments, then assessed what each achieved and how well it addressed the things patients themselves say matter. Reviews of this kind are useful because they show not only which treatments have evidence behind them but where the evidence is missing altogether.

Friedreich's ataxia is caused by too little of a protein called frataxin, so a major goal is to restore it at the source. This review from a leading center surveys the cutting-edge genetic and cellular therapies now in development, including gene therapies that add a working copy of the FXN gene and cell-based approaches. The authors weigh what each strategy has shown so far and the hurdles ahead. No such therapy is proven yet, but the pipeline aiming to change the disease course is growing quickly.

Omaveloxolone (Skyclarys) is the first approved treatment for Friedreich's ataxia and works by switching on a cellular defense pathway (Nrf2). Because the drug can affect metabolism, this real-world study tracked cholesterol and other blood fats over one year in patients taking it. Measuring these lipid changes helps clarify this side of the drug's effects and informs monitoring. Practical safety information like this helps doctors and families use the medicine well while the search for additional treatments continues.

Heart disease is the leading cause of death in Friedreich's ataxia, yet its mechanisms are not fully understood. Researchers grew heart cells from patients' own stem cells and compared them with gene-corrected versions in which the faulty GAA repeat had been removed using CRISPR. The frataxin-deficient cells showed clear heart-muscle dysfunction and widespread changes in gene activity, which the correction reversed. The model gives researchers a human system to study FRDA cardiomyopathy and to test treatments aimed at protecting the heart.

Friedreich's ataxia often strikes during the passage from childhood into adulthood, colliding with major life transitions. This study within the PROFA project used a life-events questionnaire to capture disease-, relationship-, and work-related events in 73 patients with childhood- or adult-onset disease. Both groups reported a similar number of events, mostly disease-related, but adults recognized more events, including positive ones, and greater disability was tied to more adverse events, especially in relationships. Capturing these lived experiences helps clinicians and families support people through the practical and emotional milestones of FRDA.

With only one approved treatment for Friedreich's ataxia, researchers are looking for other targets. This study examined sphingolipids, a family of fats involved in cell membranes and signalling, and found the enzymes that process them are disturbed in the disease, in both cell and animal experiments. The team then explored whether correcting that imbalance helps. It is early laboratory work, but it opens a route separate from the antioxidant approach that current treatment takes.

This is one of the first clinical trials of gene therapy for the heart disease of Friedreich's ataxia. The therapy, AAVrh.10hFXN, uses a harmless virus given by vein to deliver a working copy of the FXN gene, aiming to restore frataxin in heart muscle, which the disease damages and which is the main cause of death. The study assessed safety and early signs of benefit. It is an early-stage, non-randomized trial, but it marks an important step toward treating FRDA cardiomyopathy at its genetic root.

In Friedreich's ataxia the FXN gene itself is intact; the expanded repeat causes the DNA around it to be packed away so the gene cannot be read properly. Treatments that unpack it would restore the body's own frataxin at the source. This review traces that approach from early benzamide compounds through to newer molecules designed to home in on the specific stretch of DNA involved, and assesses how close each is to being usable.

Fruit flies are widely used to study Friedreich's ataxia because their genes can be altered quickly and cheaply. This systematic review and meta analysis pooled fly studies that identified genetic modifiers, other genes that make the effects of low frataxin better or worse. Bringing scattered experiments together shows which modifiers hold up consistently across laboratories. Modifiers matter because they help explain why patients with similar repeat lengths differ, and each one is a possible drug target.

Friedreich's ataxia usually begins with progressive difficulty walking in childhood, and when the heart is involved it is typically a thickened (hypertrophic) form. This preprint (not yet peer-reviewed) describes an unusual 14-year-old boy who presented first with heart failure and a stroke: he had severe dilated cardiomyopathy with a clot inside the heart, an ischemic stroke, and skeletal features such as high-arched feet and scoliosis, before classic neurological signs. The case is a reminder that Friedreich's ataxia can rarely announce itself through heart disease, findings that await peer review.

Loss of proprioception, the sense of where your limbs are without looking, is central to Friedreich's ataxia and drives much of the unsteadiness. This study used mice in which frataxin was removed only from certain sensory nerve cells and examined muscle spindles, the sensors inside muscle that report position. Both their structure and their function were affected, and coordination suffered. Pinpointing where in the sensory pathway the problem arises helps target treatments and choose what to measure.

Small motion sensors worn on the body can measure movement in Friedreich's ataxia more objectively than a clinician's rating scale. A practical difficulty is that a model trained on data from one setting often performs poorly on data collected elsewhere. This engineering study applies domain adaptation, a machine learning technique for bridging that gap, so the assessment holds up across different datasets. More reliable objective measures make it easier to detect small changes in trials.

Researchers created a model of Friedreich's ataxia by growing both sensory neurons and heart muscle cells from the same patients, allowing them to compare the two tissues most affected by the disease side by side. Protein analysis showed each cell type is disrupted in its own way by frataxin deficiency. They then tested a compound that binds Miro1, a protein on the outer surface of mitochondria, and found it eased some of these cell specific vulnerabilities.

A weak cough makes it harder to clear the airway and raises the risk of chest infections, a serious concern in Friedreich's ataxia. This study measured voluntary peak cough flow in people with the condition and examined how it related to lung function, mouth and tongue strength, overall disease severity and genetic factors. Identifying who is at risk allows airway clearance support to be offered before problems develop rather than after a hospital admission.

Frataxin is needed to build iron sulfur clusters, and its shortage leaves iron mishandled inside mitochondria, though how much this contributes to the disease has been debated. Using a fruit fly model based on the same GAA repeat expansion seen in patients, this preprint reports that limiting how much iron the gut absorbs corrected problems in glial support cells and lengthened the flies' lifespan. It has not yet been peer reviewed.

Friedreich's ataxia stems from a shortage of frataxin, which harms mitochondria and disables the cell's recycling system (autophagy), and no disease-modifying drug yet exists. This study tested UA-36, a water-soluble derivative of the natural compound urolithin A, in cell and mouse models. UA-36 restored frataxin levels, revived autophagy, improved mitochondrial function, and reduced oxidative damage; in mice it improved coordination, gait, and muscle strength while protecting cerebellar neurons and the heart. These preclinical results mark UA-36 as a promising lead worth developing further toward a possible therapy.

Most people with Friedreich's ataxia carry two expanded GAA repeats in the FXN gene, but some have one expansion paired with a harder-to-detect deletion. Using patients in the FACOMS natural-history study, this report describes those with proximal FXN deletions, who were initially thought to have only a single expanded copy. They had more severe disease, including higher rates of heart muscle disease, diabetes, and optic-nerve problems. The message: when standard testing finds only one expanded allele in a severely affected patient, a hidden deletion should be suspected.

Cerebellar transcranial direct current stimulation, a gentle electrical stimulation applied to the scalp, has been proposed as a treatment for ataxia. In this study 19 people with Friedreich's ataxia and 17 healthy volunteers received ten days of stimulation while researchers measured brain activity with magnetoencephalography. The stimulation did not change the brain measures examined. Reporting results that do not work is important, because it stops other groups and patients investing in an approach that lacks support.

Friedreich's ataxia usually occurs when a child inherits an over-expanded GAA repeat in the FXN gene from both parents. This study traced where these disease-causing expansions come from, identifying smaller precursor alleles (protomutations) that can grow into full expansions across generations. The findings help explain why FRDA is common in some populations and rare in others. Understanding how these expansions arise and persist sharpens genetic counseling for families and deepens the picture of the disease's origins.

Omaveloxolone was approved after a trial showed it slowed worsening on a standard Friedreich's ataxia rating scale (mFARS). This analysis pooled results from the available studies, including the original trial, its long-term extension, and real-world observations, covering 248 patients, and compared the combined outcome against the disease's expected natural decline. Bringing the evidence together helps clarify how much benefit the drug offers over time and supports doctors and families weighing treatment. It also highlights the value of longer-term data.

Because Friedreich's ataxia stems from a shortage of frataxin, one strategy is to deliver the protein into the cells that lack it. Researchers engineered a version of frataxin able to be secreted and to penetrate cells and reach the mitochondria where it is needed, delivered using blood stem cells carrying the gene. In laboratory and animal models of FRDA, the approach corrected biochemical defects and protected cells. It is an early, preclinical proof of concept for a frataxin-replacement therapy that would need testing in people.

This Cochrane review, a respected form of independent evidence synthesis, examined the medicines studied for Friedreich's ataxia to see which are supported by reliable trial evidence. It weighed drugs aimed at slowing the disease or easing its symptoms, including the approved treatment omaveloxolone, and judged the strength and limitations of the data. Reviews like this give patients and clinicians a clear, unbiased summary of what current medications can and cannot do, and point to where better trials are still needed.

Low fitness and heart involvement are common in Friedreich's ataxia, so this trial at the Children's Hospital of Philadelphia tested whether individualised exercise, a vitamin-related supplement called nicotinamide riboside (an NAD+ precursor), or both could improve cardiopulmonary fitness. Sixty-six people aged 10 to 40 were randomly assigned across four groups for 12 weeks, and exercise testing measured the change in peak oxygen uptake. The study reports safety and how each approach affected fitness. Results like these help clarify which supportive strategies are worth carrying into larger Friedreich's ataxia trials.

SGT-212 is an experimental gene therapy for Friedreich's ataxia designed to deliver a working copy of the FXN gene so cells can make frataxin, the protein patients lack. This first-in-human study gives it in two ways at once, directly into a deep brain structure (the dentate nucleus) and by vein, to reach both the nervous system and the heart. The early-stage trial is testing safety and the right dose in adults with FRDA. Ask your care team whether you might be eligible.

Omaveloxolone (Skyclarys) is approved for Friedreich's ataxia in people aged 16 and older, but not yet for younger patients. This phase 3 study is testing how well it works and how safe it is in children and teenagers with FRDA, comparing it with placebo. Extending an approved treatment to younger ages matters because the disease often begins in childhood. The study runs at many sites. Families can ask their care team whether taking part makes sense.

This study uses magnetic resonance spectroscopy, a scan that measures brain chemistry rather than structure, to track two molecules: GABA, a calming signal between nerve cells, and glutathione, an antioxidant. Researchers will compare levels in people with Friedreich's ataxia against volunteers without it, then follow patients across three timepoints over at least six months while they take omaveloxolone. The aim is to test whether these measurements work as biomarkers of the disease.

Heart muscle disease (cardiomyopathy) is a major and life-threatening part of Friedreich's ataxia, yet its course varies from person to person. CLARITY-FA is an observational study following people who have FRDA-associated cardiomyopathy to document how it develops over time. It does not test a drug, but the detailed heart data it gathers help researchers understand the condition and design and interpret trials of heart-directed therapies, including gene therapies. Ask an FRDA center whether joining could be right for you.

CTI-1601 (nomlabofusp) is an investigational therapy that aims to replace the missing frataxin directly, delivering the protein into cells by injection under the skin. This open-label phase 2 study evaluates the safety and effects of long-term daily dosing in children, adolescents, and adults with Friedreich's ataxia, including those who took part in earlier CTI-1601 studies. Because FRDA is caused by a frataxin shortage, restoring the protein is a direct approach. Ask your care team whether you might be eligible.

Swallowing difficulty, or dysphagia, is one of the disabling features of Friedreich's ataxia, affecting nutrition, safety and daily life. Omaveloxolone was approved in early 2024 as the first treatment for the condition, and this French study in Nice asks specifically whether it improves swallowing. It is recruiting. Testing a drug against one troublesome symptom, rather than only against an overall rating scale, addresses a question families often raise about what a treatment will change day to day.

This observational study follows people already prescribed omaveloxolone, sold as Skyclarys, by their own doctors, to record how the drug behaves over the long term outside a controlled trial. Participants are identified through the Friedreich's Ataxia Global Clinical Consortium's UNIFAI natural history study, a network of centres that both treat patients and gather research data. Their usual care is unchanged. It is recruiting across the United States and six European countries, including Austria, Belgium, Germany, Italy and the Netherlands.

Friedreich ataxia is caused by a GAA repeat expansion in the frataxin gene, and its severity varies partly with how large that expansion is. This French study uses ultrasound to measure the size of peripheral nerves in people with the condition, looking for a structural marker that can be seen without invasive testing. It is recruiting in Nice. Simple imaging measures matter now that treatments exist, because trials need reliable ways to show whether nerves are changing.

Most Friedreich's ataxia studies measure neurological scores. This one asks patients themselves what the condition costs them, collecting reported outcomes alongside health economic and psychosocial measures. That evidence is what health systems use when deciding whether to fund an expensive treatment, and it is often the piece that is missing when a rare disease drug reaches a reimbursement decision. The study is recruiting.

This trial is testing AAVrh.10hFXN, a gene therapy for the heart disease of Friedreich's ataxia. Given by vein, it uses a harmless virus to deliver a working copy of the FXN gene so heart muscle can make frataxin, which the disease depletes. The early-phase study evaluates safety and preliminary effectiveness at escalating doses, with a short course of a steroid (prednisone). Because cardiomyopathy is the main cause of death in FRDA, treating it at the genetic root is a key goal. Ask your care team about eligibility.

Fatigue is one of the most limiting symptoms in Friedreich's ataxia and one of the least explained. Because the condition also affects the heart muscle, this study tests whether how much blood the heart pumps accounts for some of that exhaustion. If the two turn out to be linked, fatigue becomes something that might be measured and treated through the heart.

LX2006 is a gene therapy for the heart disease that accompanies Friedreich's ataxia. It uses an adeno-associated virus, given once through a vein, to carry a working copy of the human frataxin gene to heart cells. This early-phase study tests up to three dose levels in people who already show cardiomyopathy, following safety and effect over 52 weeks and then for a further four years, five in total. It is active but no longer recruiting.

Vatiquinone is an experimental drug for Friedreich ataxia that targets oxidative damage in cells. This study follows participants who had already taken vatiquinone in an earlier trial, to assess how safe it is over a longer period. It runs across nine countries, including the United States, Australia, Brazil, Canada, France, Germany, Italy, New Zealand and Spain, and is active but no longer recruiting. Extension studies like this are how long-term tolerability is established after a shorter trial ends.

This Florida study measures how the heart and the nerves and muscles perform in people with Friedreich's ataxia, using echocardiography, MRI, exercise testing that tracks metabolism, and neurophysiological recordings. The aim is to establish measures sensitive enough to show change, which is what any treatment trial depends on. It is recruiting. Because the condition affects both the nervous system and the heart, having matched measures of each in the same participants is particularly useful.

This study records the brain's electrical activity in people with Friedreich's ataxia to map how brain regions are wired together and how well they communicate. Friedreich's is usually thought of as a disease of the spinal cord, nerves and cerebellum, so evidence about wider brain networks addresses a real gap. EEG is inexpensive and non-invasive, which makes it attractive as a possible progression measure. The study is recruiting.

UNIFIED is a large, global observational study run by the Friedreich Ataxia Global Clinical Consortium. It follows people with FRDA over time at many centers, carefully tracking how the disease progresses. It does not test a treatment, but the standardized data it collects are essential for understanding the disease and for developing and testing safe, effective therapies, and it helps connect patients with the research network. Ask an FRDA clinic near you whether taking part is possible.

DT-216P2 is an experimental medicine designed to switch the silenced FXN gene back on so cells can make more frataxin, addressing the root cause of Friedreich's ataxia. This early trial gives repeated, increasing doses to adults with FRDA to evaluate safety, tolerability, and how the drug behaves in the body. Because the FXN gene in FRDA is turned down rather than missing, reactivating it is a promising strategy. Ask your care team whether a study like this could be an option for you.

Losing balance while standing is one of the earliest and most disabling problems in Friedreich's ataxia. This trial tests whether training on a stabilometric platform, a device that measures body sway and gives immediate feedback, improves standing balance. It is a rehabilitation study rather than a drug study, aimed at the kind of function people notice day to day. The study is recruiting.

DT-216P2 is being developed to raise production of frataxin, the protein that people with Friedreich's ataxia cannot make enough of. This is a first-stage safety study in healthy volunteers, given as single increasing doses, so no benefit is expected or measured here. Studies of this kind establish what doses can be tolerated before a drug is tested in patients. It is listed as not yet recruiting.

TRACK-FA follows about 200 children and adults with Friedreich ataxia, plus 100 matched comparison participants, across six academic centres in five countries. Everyone is scanned at the start and again at 12 and 24 months, so the study can show how brain and spinal cord imaging changes as the disease progresses. Clinical and cognitive measures and exploratory blood markers are collected too. It is active but no longer recruiting new participants.

Drug trials in a rare disease depend on having measures sensitive enough to detect change over a realistic period. This long-running study is building and validating exactly those clinical outcome measures for Friedreich's ataxia, tracking participants over time to see which scales move and how fast. Work like this rarely makes headlines but decides whether later trials can prove anything. The study is active but no longer recruiting.

This UK study, run with a mitochondrial research centre, examines balance and walking in Friedreich's ataxia in detail. Gait and balance are what most affects independence in the condition, and precise measurement of both is needed before any treatment can be shown to preserve them. The study is active but no longer recruiting.

Transcranial direct current stimulation passes a weak electrical current through the scalp to the cerebellum, the part of the brain most affected in Friedreich's ataxia. This study tests whether repeating those sessions, rather than giving a single one, produces a clinical benefit. It is a non-drug approach that could in principle be combined with medication. The study is active but no longer recruiting.

This Belgian study tests whether electrical stimulation applied to the cerebellum eases the symptoms of Friedreich's ataxia. Participants are assigned in random order, so each person acts partly as their own comparison, which helps separate a real effect from the improvement people often report simply from taking part. The study is active but no longer recruiting.